A Phase II, Open Label, Randomised, Single Centre Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three or Four Doses of Meningococcal Serogroup B Outer Membrane Vesicle (OMV) Vaccine MENZBTM When Administered to Healthy Adults (University Students).
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2015
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- 04 Dec 2008 Checked against ClinicalTrials.gov record. Last reviewed 4 Dec 2008.
- 26 Sep 2007 Status change from in progress to completed.
- 10 Apr 2007 New trial record.